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Summary
 
We isolated a new mouse gene that is highly expressed in thymocytes, testis, and brain. This
gene, 
 
SRG3
 
, showed a significant sequence homology to 
 
SWI3
 
, a yeast transcriptional activator,
and its human homolog 
 
BAF155. SRG3
 
 encodes 1,100 amino acids and has 33–47% identity
with SWI3 protein over three regions. The SRG3 protein contains an acidic NH
 
2
 
 terminus, a
myb-like DNA binding domain, a leucine-zipper motif, and a proline- and glutamine-rich re-
gion at its COOH terminus. Rabbit antiserum raised against a COOH-terminal polypeptide of
the SRG3 recognized a protein with an apparent molecular mass of 155 kD. The serum also
detected a 170-kD protein that seems to be a mouse homologue of human BAF170. Immuno-
precipitation of cell extract with the antiserum against the mouse SRG3 also brought down a
195-kD protein that could be recognized by an antiserum raised against human SWI2 protein.
The results suggest that the SRG3 protein associates with a mouse SWI2. The SRG3 protein is
expressed about three times higher in thymocytes than in peripheral lymphocytes. The expres-
sion of anti-sense RNA to SRG3 mRNA in a thymoma cell line, S49.1, reduced the expres-
sion level of the SRG3 protein, and decreased the apoptotic cell death induced by glucocorti-
coids. These results suggest that the SRG3 protein is involved in the glucocorticoid-induced
apoptosis in the thymoma cell line. This implicates that the SRG3 may play an important reg-
ulatory role during T cell development in thymus.
 
P
 
rogenitor T cells arise in the bone marrow and migrate
to thymus, where they continue to develop. During
the T cell development, more than 95% of developing im-
mature thymocytes die by apoptosis as a consequence of
negative selection or lack of positive selection (1). This apop-
totic death targets mainly the cortical double-positive
(CD4
 
1
 
CD8
 
1
 
) thymocytes. In thymocytes, apoptosis can be
triggered by several exogenous stimuli such as glucocorti-
coids (2–4), removal of growth factors (5, 6), exposure to
 
g
 
-irradiation (7), and antigen binding involving the CD3/
TCR (8–10). The effect of glucocorticoids (GCs)
 
1
 
 is selec-
tive; the immature CD4
 
1
 
CD8
 
1
 
 thymocyte fraction is rap-
idly killed by GC treatment, whereas both the precursor
population (TCR
 
2
 
CD4
 
2
 
CD8
 
2
 
) and mature thymocytes
(CD4
 
1
 
 or CD8
 
1
 
) are relatively resistant (11). It was re-
ported that GC is produced within the thymus (12), and
that transgenic expression of anti-sense RNA to glucocor-
ticoid receptor (GR) significantly affects the thymocyte de-
velopment (13). These results suggest that endogenous GC
produced in thymus may participate as an important regu-
latory molecule of normal thymic development (14, 15).
GCs, when complexed with an activated receptor, can
induce or inhibit the expression of specific genes, which
may be related to the induction of apoptosis. The transcrip-
tional regulation of downstream genes by GCs requires not
only GR itself but several additional transcription factors
such as the SWI–SNF protein complex (16–20). For exam-
ple, the rat GR, when expressed in yeast, requires SWI–SNF
proteins for transcriptional activation of GR-responsive
genes and the GR–SWI3 complexes were coimmunopre-
cipitated in yeast extract (19, 20). In addition, antibodies
against SWI3 interfere with the ability of rat GR to activate
transcription in 
 
Drosophila melanogaster
 
 nuclear extracts (19).
SWI3 is a subunit of the SWI–SNF complex that seems
 
1
 
Abbreviations used in this paper:
 
 GC, glucocorticoids; GR, glucocorticoid
receptor; GST, glutathione-S-transferase; IP, immunoprecipitation; MACS,
magnetic activated cell sorter; PI, propidium iodide.
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to facilitate transcriptional activation by antagonizing the
repressive actions of chromatin (21–23). The other subunits
of the SWI–SNF complex so far identified include the
SWI1 (ADR6), SWI2 (SNF2), SNF5, SNF6, SNF11, and
SWP73. The complex was initially identified in 
 
Saccharomy-
ces cerevisiae
 
 (
 
S. cerevisiae
 
) as a positive regulator of 
 
HO
 
, a gene
involved in mating type switching (24, 25), and 
 
SUC2
 
, a
glucose-repressible gene that encodes the enzyme invertase
(26, 27). These 
 
SWI
 
 gene products were subsequently
found to be required for the transcriptional activation of
many other genes (28–31). Such activities of the SWI–SNF
proteins are closely interconnected and they seem to func-
tion as components of a complex that associates with gene-
specific activators (31–35). The functional significance of
the SWI–SNF complex is reflected by the evolutionary
conservation of these genes in higher eukaryotes. Several
higher eukaryotic homologues of 
 
SWI–SNF
 
 genes such as
 
Drosophila
 
 homeotic gene activator 
 
brm
 
, 
 
hbrm
 
 (also known
as 
 
hSNF2
 
a
 
) and 
 
BRG1
 
 (also known as 
 
hSNF2
 
b
 
) have been
identified (36–39). In addition, a human protein homo-
logue of SNF5 (40, 41) and mouse BAF60 (42), which is
homologous to SWP73, have been identified. Recently,
distinct complexes containing the 
 
BRG1
 
 or 
 
hbrm
 
 that have
an in vitro activity similar to yeast SWI–SNF have been
purified from human cell lines (42, 43). From these com-
plexes, the human BAF155 and BAF170 proteins that are
homologous to SWI3 protein were identified (42).
In this paper, we describe a newly isolated mouse gene,
the 
 
SWI3
 
-related gene (
 
SRG3
 
), expressed in thymus and
encoding a protein that shows significant amino acid se-
quence homology to both yeast SWI3 and human BAF155
proteins. The SRG3 protein coimmunoprecipitates with a
mouse SWI2-like protein, suggesting their forming a pro-
tein complex in vivo. In addition, our data show that the
SRG3 is expressed at much higher level in thymus than in
peripheral lymphocytes. Because the GC is proposed to be
a regulatory molecule in thymocyte development in thy-
mus, and the SWI-related proteins have an important role
in GC-mediated gene regulation, the high level expression
of 
 
SWI3
 
-related gene (
 
SRG3
 
) in thymocytes may imply
that SRG3 has a crucial role in thymocyte development as
a mediator of GC-induced transcriptional activation and
apoptotic cell death of thymocytes. As a first step of testing
this hypothesis, we analyzed the effect of downregulation
of SRG3 expression in a GC-sensitive thymoma cell line
on GC-induced apoptosis.
 
Materials and Methods
 
Mice and Cells.
 
C57BL/6J mice were maintained in the Insti-
tute for Molecular Biology and Genetics (Seoul National University,
Seoul, Korea). The yeast strain 
 
CY165
 
 (
 
MAT
 
a
 
, 
 
swi3
 
D
 
 
 
::
 
 
 
trp1-
 
D
 
1
 
,
 
HO–lacZ
 
, 
 
ura3-52
 
, 
 
leu2-
 
D
 
1
 
, 
 
his3-
 
D
 
200
 
, 
 
ade2
 
-
 
101
 
, 
 
lys
 
-
 
801
 
) cells,
and yCP50 plasmid containing the 
 
SWI3
 
 gene were gifts from C.
Peterson (University of Massachusetts, Worcester, MA). Yeast
cells were grown in synthetic minimal medium (0.67% Bacto-
yeast nitrogen base without amino acids; GIBCO BRL, Gaithers-
burg, MD) supplemented with leucine, histidine, adenine, and ly-
sine to a mid-log phase. The mouse thymoma cell line, S49.1, was
purchased from American Type Culture Collection (ATCC,
Rockville, MD) and grown in DMEM supplemented with 10%
fetal bovine serum.
 
Isolation and Purification of Poly(A)
 
1
 
 RNA.
 
Total RNA was iso-
lated by CsCl banding, as described by Chomczynski and Sacchi
(44). Intact thymi and spleens were collected from 3-5-wk-old
mice and used as sources for RNA. Poly(A)
 
1
 
 RNA was isolated
by oligo(dT)–cellulose chromatography (45).
 
Preparation of Subtractive Probe.
 
z
 
10 
 
m
 
g of poly(A)
 
1
 
 RNA was
heated at 65
 
8
 
C for 2 min and annealed with 1 mg of magnetic
beads containing oligo (dT) (Dynabeads oligo [dT]
 
25
 
; Dynal, Inc.,
Great Neck, NY) for 30 min at room temperature (46). The an-
nealed poly(A)
 
1
 
 RNA was separated in magnetic field, and used
as templates for the synthesis of the first-strand cDNA. The sec-
ond-stranded cDNA was synthesized by random priming using
hexanucleotides and 200 
 
m
 
Ci of [
 
a
 
-
 
32
 
P]dCTP (3,000 Ci/mmol).
To prepare a subtractive probe, 200 
 
m
 
g of the first-stranded
spleen cDNA conjugated with magnetic beads were mixed with
the labeled probe. After incubating at 55
 
8
 
C for 1 h, the labeled
probe DNAs hybridized to the first-stranded spleen cDNA were
removed using magnetic field, and the remaining subtractive
probe was used for the screening of thymic cDNA library. The
cDNA library was obtained from M.M. Davis at Stanford Uni-
versity (Stanford, CA).
 
DNA Sequencing and Computer Analysis.
 
To determine the
nucleotide sequences, the restriction fragments of the cloned
gene were subcloned into pBluscript (SK
 
2
 
) vector (Stratagene
Inc., La Jolla, CA). Nested deletions were generated by the Erase-
a-Base system (Promega Corp., Madison, WI). The nucleotide
sequence was determined by dideoxy chain termination method
(47) using Sequenase 2.0 kit (United States Biochemical Corp.,
Cleveland, OH). Homology searches of the nucleotide and de-
duced amino acid sequences with sequences were performed at
the National Center for Biotechnology Information, using the
BLAST network service (48).
 
Separation of T and B Cell.
 
Single cell suspensions were pre-
pared from intact spleens and lymph nodes of C57BL/6J mice.
After the red blood cells were removed, cells were resuspended in
PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na
 
2
 
HPO
 
4
 
, 1.4 mM
KH
 
2
 
PO
 
4
 
, pH 7.3). To isolate T cells, single cell suspensions were
sequentially reacted with biotinylated H57-597 antibody, which
is specific to 
 
ab
 
 TCR, and streptavidin-conjugated microbeads.
The B cells were reacted with microbead-conjugated goat anti–
mouse IgM. The cell-magnetic bead conjugates were separated
by a magnetic cell sorter (MACS; Miltenyi Biotec, GmbH, Ber-
gisch Gladbach, FRG) (49). The purity of isolated populations
were confirmed by FACS
 
Ò
 
 (Becton Dickinson, Mountain View,
CA) analysis and Northern blot assay using 
 
TCF-1
 
, a T cell–spe-
cific gene, as a probe.
 
Overexpression and Purification of GST–fusion Protein.
 
For the con-
struction of GST–fusion protein, COOH-terminal region of the
 
SRG3
 
 gene was inserted into pGEX4T-2 vector in frame. 
 
DH5
 
a
 
cells harboring recombinant plasmids with GST–3C fusion were
grown overnight and diluted to 1:200 in 200 ml of LB medium.
After incubation at 37
 
8
 
C for 2 h with vigorous shaking, the cul-
ture was treated with 1 mM IPTG and then incubated for 3 h to
induce expression of the fusion protein. Cells were harvested and
resuspended in a sample loading buffer (50 mM Tris–HCl, pH
6.8, 100 mM DTT, 4% SDS, 0.2% BPB, 20% glycerol), and
boiled for 2 min. These lysates were analyzed by electrophoresis
on polyacrylamide gel. The overexpressed protein was purified
by glutathion–sepharose 4B affinity chromatography as described 
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by Smith and Johnson (50). The polyclonal antiserum was pre-
pared by immunizing New Zealand white rabbit with the puri-
fied fusion protein.
 
Immunoprecipitation and Immunoblot Analysis.
 
The immunopre-
cipitation of the SRG3 and SWI2-like protein was performed by
a method described by Muchardt et al. (40) with some modifica-
tions. The single cell suspension of the mouse thymus was har-
vested in immunoprecipitation (IP) buffer (20 mM Hepes, pH
7.6, 10% glycerol, 25 mM MgCl
 
2
 
, 0.1 mM EDTA, 0.2% NP-40)
containing 0.1 M potassium acetate and 2.25 
 
m
 
g/ml pepstatin, 10
 
m
 
g/ml leupeptin, 1 
 
m
 
g/ml soybean inhibitor, 2 mM PMSF, and
0.1 mM DTT. The cells were sonicated and debris were pelleted
by centrifugation. The extracts were precleared with protein
A–sepharose suspension and anti-SRG3 or anti-hSWI2 rabbit an-
tiserum were added. After overnight incubation at 4
 
8C, the ex-
tracts were incubated with protein A–sepharose suspension. The
beads were washed three times in IP buffer containing 0.6 M po-
tassium acetate, and once with IP buffer without Hepes. The pre-
cipitate was eluted by boiling in SDS-PAGE loading buffer. For
immunoblot analysis, the proteins separated on SDS-PAGE were
electrotransferred to nitrocellulose paper, and incubated in block-
ing solution (3% non fat dry milk, 50 mM Tris–HCl, pH 7.5, 150
mM NaCl) with gentle agitation for 2 h. After the blot was incu-
bated with the SRG3 antiserum or hSWI2 antiserum, the specific
bands were detected by treating the blot with anti-rabbit IgG con-
jugated with alkaline phosphatase in blocking solution (100 mM
Tris–HCl, pH 9.5, 100 mM NaCl, 10 mM MgCl2) containing
165 mg/ml BCIP and 330 mg/ml NBT.
Complementation of Yeast swi32 Mutant. For complementation
study, the SWI3–SRG3 hybrid gene encoding the NH2-terminal
part of SWI3 and the COOH-terminal part of SRG3 was synthe-
sized. The full-length SRG3 gene or the SWI3–SRG3 hybrid gene
were inserted into the pRS316GU vector containing the URA3
promoter and the URA3 gene as auxotrophic marker. The result-
ing constructs were used to transform CY165 yeast cells that har-
bor swi32 mutation and the HO–lacZ fusion gene construct. The
Ura1 cells were cultured in synthetic minimal media. Cells were
collected when OD595 of the culture reached 0.5. b-gal assay was
performed as described by Breeden and Nasmyth (51). The Cp15
construct that contains the SWI3 gene in yCP50 vector was also
used to transform CY165 cells as a positive control.
Preparation of the Glycerol Density Gradient Sedimentation Fraction
from Thymocytes Extract. The thymocytes were prepared as a sin-
gle cell suspension from thymi and homogenized in 700 ml extrac-
tion buffer (40 mM Hepes, pH 7.3, 200 mM NaCl, 0.5 mM DTT,
2 mM EDTA, and 2.25 mg/ml pepstatin, 10 mg/ml leupeptin,
1 mg/ml soybean inhibitor). After centrifugation at 12,000 rpm
for 20 min at 48C, the supernatant containing 7.2 mg of total pro-
tein in 400 ml was layered on the top of linear 18–40% 10 ml
glycerol gradient cushion containing 40 mM Hepes, pH 7.3, 200
mM NaCl. After ultracentrifugation at 36,500 rpm in Beckman
SW41 rotor for 20 h at 48C, the samples were collected from the
bottom of the tube by fractionation into 33 tubes. These fraction-
ated samples were analyzed by immunoblotting with SRG3 or
hSWI2 antiserum.
Construction of a Plasmid Expressing Anti-sense RNA of the SRG3
Gene. A 2.8 kb XbaI fragment spanning 60 bases of 59-untrans-
lated region and 2772 bases of the SRG3 coding sequence was
inserted into the pRc/CMV vector (Invitrogen, San Diego, CA)
in the anti-sense orientation. The resulting plasmid was designated
as pRcASRG3. The plasmid construct, pRcASRG3, or pRc/CMV
was transfected into S49.1, a thymoma cell line (ATCC), by
electroporation. The transfected cells were selected and main-
tained with 1 mg/ml Geneticin (GIBCO BRL, Gaithersburg, MD)
in DMEM supplemented with 10% fetal bovine serum.
Induction and Measurement of Apoptosis. The apoptotic cell death
of thymoma cells were induced by treatment with 10 mM hydro-
cortisone (Sigma Chem. Co., St. Louis, MO) for 72 h at 378C. Af-
ter hydrocortisone treatment, the cells were harvested and lysed
in lysis buffer (10 mM EDTA, 50 mM Tris–HCl, pH 8.0, 0.5%
sodium lauryl sarcosine) containing the 100 mg/ml proteinase K
at 558C for 2 h. The DNA was extracted with phenol/chloro-
form and precipitated with ethanol. After RNA was removed by
RNAse A treatment, the DNA was analyzed in agarose gel elec-
trophoresis to visualize the fragmented DNA. The apoptotic cell
death was also measured by flow cytometry as described by Nico-
letti et al. (52). In brief, the harvested cells were fixed with 70%
ethanol and stained with 50 mg/ml of propidium iodide (PI) and
10 mg/ml RNAse A for 30 min at 48C. After washing with PBS
buffer, stained cells were analyzed using the FACStarÒ (Becton
Dickinson, Mountain View, CA) for the DNA content.
Results
Cloning and Characterization of the Mouse SWI3-related
Gene (SRG3). We made an attempt to isolate genes that
are specifically expressed in thymus but not in spleen by
subtractive hybridization. One of the clones isolated was
found to be expressed preferentially in thymus and was
found to have similar amino acid sequences to a part of
SWI3 protein of S. cerevisiae. The isolated gene has an open
reading frame of 3,300 bp encoding 1,100 amino acids
(Fig. 1). The homology search in the GenBank sequence
database of NCBI using the BLASTP program showed
amino acid sequence similarity to the SWI3 protein of S.
cerevisiae (Fig. 2). The new gene was named as SRG3 to
emphasize its relatedness to SWI3 gene.
Figure 1. Amino acid sequence of the SRG3 gene predicted from
cDNA sequence. The predicted leucine-zipper motif is indicated by as-
terisks, and the myb-like tryptophan repeat is indicated by the closed tri-
angles. The regions showing highest homology to the yeast SWI3 are un-
derlined. These sequence data are available from EMBL/GenBank/DDBJ
under accession number U85614.1830 SRG3 Required for Glucocorticoid-induced Apoptosis
The NH2-terminal part of the SRG3 is highly acidic;
23% of 231 amino acids (211–441) are either aspartate or
glutamate. The COOH-terminal part has the leucine-zip-
per motif (53), and the proline- and glutamine-rich region.
The proline and glutamine residues make up 44% over 150
amino acids (952–1,100). In addition, the myb-like tryp-
tophan repeat domain or SANT (SWI3, ADA2, N-CoR,
and TFIIIB B99) domain (54), which may be involved in
interaction with DNA, was also found in the middle part of
this protein (Fig. 2 A). Therefore, this gene product seems
to act as a transcriptional activator probably by interacting
with other proteins or by interacting with DNA.
Recently, the human homologues of yeast SWI3, BAF155,
and BAF170, were identified and designated as BRG1 as-
sociated factors (42). We found that the SRG3 protein has
very high amino acid sequence homology to BAF155 pro-
tein (Fig. 2). They show 91% identity in their complete
amino acid sequences, with the major deviations occurring at
the NH2 termini. Therefore, we conclude that the SRG3
protein is the murine counterpart of human BAF155 protein.
The SRG3 protein also matches well with the BAF170,
another human SWI3 homologue; they are 60% identical
and 70% similar at the amino acid level. In addition, the
SRG3 protein has a considerable homology with the yeast
YFK7 protein, which is also known as SWI3b (42) (Fig. 2).
The major similarity between the SWI3 and its mamma-
lian homologues at the amino acid level is found over three
regions (Fig. 2 B). The three regions of the SWI3 and
SRG3 proteins shows 33–47% identity and 61–64% simi-
larity. The NH2-terminal part of the SWI3 is also ex-
tremely acidic, yet similarity with the SRG3 is still very
low. The leucine-zipper motifs in the region III of these
proteins are different from SWI3 in that the third leucine
of the SWI3 protein is replaced by phenylalanine in SRG3
and BAF155 (Fig. 2 C). In the COOH-terminal region,
SWI3 lacks proline- and glutamine-rich regions found in
its mammalian homologues. The data suggests that these
proteins have similar protein structures and probably similar
biochemical functions. However, there is divergence in
structure and, probably, also in function between these
proteins.
Identification of the SRG3 Gene Product. To identify the
protein product of the SRG3 gene, polyclonal antibody
was produced against the SRG3–GST fusion protein. The
COOH-terminal part of the SRG3 gene was inserted in-
frame into the pGEX4T-2 plasmid containing the gluta-
thione-S-transferase (GST) gene. The overexpressed GST–
3C fusion protein with z85 kD of molecular mass was
used to immunize rabbits through subcutaneous injection.
After primary and booster injections, polyclonal antiserum
against GST–3C fusion protein was obtained. The antise-
rum was confirmed to recognize specifically the fusion pro-
tein (data not shown). To identify the SRG3 gene product,
immunoblot analysis was performed with crude extracts
prepared from thymus and lymph node. As shown in Fig.
3 A, two bands of z155 and 170 kD were observed; the
155-kD protein is likely to be SRG3. This is supported by
the observations that the protein matches well to the size of
Figure 2. The comparison of amino acid sequences of the SRG3 with SWI3 and its human homologues, BAF155 and BAF170. The YFK7, another
yeast homologue of SWI3, is also presented. The regions showing highest homology are shown by rectangles with distinctive fillings (A). The SRG3 and
human homologues of SWI3 protein contain the proline- and glutamine-rich domains that lack in the yeast SWI3. Amino acid comparisons of the three
regions (Region I, II, and III) are shown in B and C. The three homologous regions of SRG3 and SWI3 protein displayed 33–47% identity and 61–64%
similarity. The amino acids that are identical to consensus sequences are indicated as dots (C).1831 Jeon et al.
the BAF155 in human (42), that the antiserum immuno-
precipitates the 155-kD protein (Fig. 3 B), and that the in-
tensity of the 155-kD protein band was specifically reduced
when anti-sense RNA to the SRG3 is expressed in a cell
line (see Fig. 6 A). The antiserum also recognized a 170-kD
protein that seemed to be similar to the SRG3 protein in
its structure. Considering the results of human SWI3 ho-
mologues (42), it is likely that the 170-kD protein may be
the mouse counterpart of the human BAF170 protein. The
SRG3 and BAF170 are quite similar to each other over re-
gions I (86%), II (93%), and III (89%) (see Fig. 2 B), and
anti-SRG3 antiserum seems to recognize a murine BAF170-
like protein as well as SRG3. Interestingly, SRG3 is ex-
pressed at a three times higher level in thymus than in lymph
nodes; however, the 170-kD protein is expressed at similar
levels in both tissues.
We tested whether the SRG3 protein is associated with
other proteins such as a mouse SWI2-like protein. After
immunoprecipitation of cell extract with the antiserum fol-
lowed by blotting with the same antiserum, the specific
band of 155 kD was observed (Fig. 3 B, bottom). We have
also employed the hSWI2 antiserum that recognized a pro-
tein with molecular mass z195 kD in thymocyte extract
(Fig. 3 B). The 195-kD protein is similar to the size of
hSWI2 (43) and seems to be a mouse homologue of
hSWI2. When thymocyte extract was immunoprecipitated
with the SRG3 antiserum and blotted with the hSWI2 an-
tiserum, a specific band corresponding to the mouse SWI2-
like protein was detected (Fig. 3 B, top). These results sug-
gest that the SRG3 associates with a SWI2-like protein and
possibly with other SWI–SNF proteins.
The SRG3 Protein Does Not Complement the Yeast swi32
Mutant. To test the possibility that the mouse SRG3 gene
product complements the yeast swi32 mutation, the S. cere-
visiae host strain CY165 (swi32) containing the HO–lacZ
gene (25) was transformed with the pRS316GU vector con-
taining the SRG3 full coding sequence or SWI3–SRG3
hybrid gene at the downstream of the URA3 promoter.
Cells transformed with the SWI3–SRG3 hybrid gene were
confirmed to express the hybrid protein by Western blot-
ting using the SRG3 and SWI3 antisera (data not shown).
The growth rate of swi32 mutant was very slow (33) and
was not significantly changed after the transformation with
either the SRG3 or the SWI3–SRG3 hybrid. In addition,
expression of lacZ gene, controlled by the HO promoter
which requires the SWI–SNF protein complex for tran-
scriptional activation, was not induced after the transforma-
tions of SRG3 or SWI3–SRG3 hybrid. The level of ex-
pression of lacZ gene in the SRG3 transformant was only
z22% of the mutant cells transformed with the yeast SWI3
(a positive control), whereas the LacZ expression level in
mutant cells transformed only with a vector plasmid was
z20% of the SWI3 transformed cells. The result was con-
sistent in three independent experiments.
The SRG3 mRNA Is Expressed Highly in Thymocytes,
Brain, and Testis. Northern blot analysis of SRG3 gene
expression showed that the transcripts of this gene were
3.5 and 5 kb in size (Fig. 4 A). It seems that the 5.0-kb
mRNA encodes the SRG3 protein because the 3.5-kb
mRNA is not long enough to include the 3,300-base open
reading frame, 59- and 39-untranslated regions, and poly(A)
tail. At this point, it is not clear what the 3.5-kb mRNA
species encodes for. However, when a 1.5-kb PstI fragment
from the 39-end of the SRG3 gene was used as a probe, only
the 5-kb transcript was detected (data not shown), suggest-
Figure 3. Immunoblotting and immunoprecipitation of the SRG3
protein. The overexpressed COOH-terminal part of SRG3 gene in Esche-
richia coli system was used to immunize rabbits to produce the polyclonal
antiserum. When thymus and lymph node extract were blotted with the
SRG3 antiserum, bands at 155 and 170 kD were detected (A). When the
extract was blotted with the hSWI2 antiserum, a band at 195 kD (B, top)
was detected. After immunoprecipitating the extract with the SRG3 anti-
serum, the precipitates were blotted with the SRG3 antiserum (B, bottom)
or the hSWI2 antiserum (B, top), displaying the 155- and 195-kD bands, re-
spectively. Immunoprecipitation with preimmune serum and blotting with
the SRG3 and hSWI2 antiserum dose not show any band (B). TCL, total
cell lysate; IP:Pre, immunoprecipitation with the pre immune serum; IP:
anti-SRG3, immunoprecipitation with the SRG3 antiserum.
Figure 4. Northern blot analysis of SRG3 gene expression in different
organs (A) and cell types (B). The same amount (15 mg) of total RNAs
isolated from various tissues were analyzed by probing with a 1.8-kb Hind-
III fragment (bases 653–2361). (A) The lanes represent thymus (1), spleen
(2), brain (3), lymph nodes (4), testis (5), and lung (6). Two transcripts of
about 5 and 3.5 kb in size were expressed highly in thymus (lane 1), brain
(lane 3), and testis (lane 5). (B) Both T and B cell expressed the SRG3.
Lane 1, thymus; lane 2, T cells; lane 3, B cells. Normal T and B cells were
separated from spleen and lymph nodes by magnetic activated cell sorter
(miniMACS). The purity of the separated population was tested by prob-
ing the RNA blot with TCF-1 (closed arrowhead). Both B and T cells ex-
pressed about the same levels of SRG3, as judged by the control b-actin
probe (open arrowhead).1832 SRG3 Required for Glucocorticoid-induced Apoptosis
ing the possibility that these two transcripts are different at
their 39 termini. The SRG3 gene is expressed at higher lev-
els in thymus, brain, and testis than in other tissues (Fig. 4
A). Northern blot analysis with RNAs isolated from sepa-
rated splenic T and B cell populations showed that the two
populations express similar level of SRG3. The separated
population was highly pure, as judged by the Northern blot
using  TCF-1 gene, a T cell–specific gene (55, 56), as a
probe (Fig. 4 B) and by FACSÒ analysis (data not shown).
Interestingly, however, the level expressed in each periph-
eral lymphocyte population was only about 20% of that ex-
pressed in thymocytes (Fig. 4 B), as it was similarly shown
by Western blot analysis (see Fig. 3 A).
The Function of the SRG3 Protein in Thymocytes. As shown
in Fig. 3 A and Fig. 4, the level of SRG3 expression in thy-
mus was much higher than the level in peripheral lympho-
cytes. Therefore, even though these proteins may form the
SWI–SNF complex together with other proteins in mouse
cells, it is also possible that the SRG3 protein exists inde-
pendently of the SWI–SNF complex, especially in thymus.
It has also been suggested that the SWI–SNF complexes are
present as multiple forms in different tissues and cell lines
(42). To see whether SRG3 protein exists mostly as a SWI–
SNF complex, we fractionated the thymus extract accord-
ing to the size of molecules by a glycerol density gradient.
Each fraction was run on a gel and immunoblotted with
the anti-SRG3 and the anti-hSWI2 antiserum. As shown
in Fig. 5, the mouse SWI2 protein was mostly fractionated
as a 2 MD complex as previously reported (42). However,
the SRG3 protein was detected in a broad range of molec-
ular masses, from 150 kD to 2 MD. Interestingly, a major
portion of the protein was fractionated as 300 kD. The
170-kD protein was also fractionated similarly to SRG3
protein. These results suggest that a major portion of the
SRG3 protein (and the 170 kD protein) exists indepen-
dently of the SWI–SNF complex and that they may play a
special role in developing thymocytes. This was similarly
reported for BAF155 and BAF170 proteins; some BAF155
and BAF170 are not associated with human SWI–SNF
complexes (42).
One of the roles played by the SRG3 or the SWI–SNF
complex in thymus may be mediating GR-induced tran-
scriptional activation. One consequence of it is the induc-
tion of GC-mediated apoptosis in immature thymocytes.
Thus, we have tested whether the SRG3 is required for the
GC-mediated apoptosis in GC sensitive thymocyte cell line.
A plasmid expressing the SRG3 gene in anti-sense orienta-
tion under the control of CMV promoter (pRcASRG3)
was constructed. The pRcASRG3 construct was introduced
into a GC-sensitive thymoma cell line, S49.1, through DNA
transfection, and two clones, clone A and B, displaying re-
duced expression of SRG3 were selected. As shown in Fig.
6 A, clone A and B express z50 and 30% SRG3 protein of
the vector transfectants, respectively. The DNA fragmenta-
tion induced by GC treatment was greatly reduced in these
clones and this effect was more dramatic in clone B, which
expressed lower level of SRG3 protein than clone A (Fig. 6 B).
The reduction in apoptotic cell death of the pRcASRG3
transfectants was also confirmed by FACSÒ analysis of the
DNA contents of the cells. After GC treatment, about 46%
of the vector transfectants were subdiploid and apoptotic
(Fig. 6 C, c); however, only about 4% of the treated clone
B transfectants were apoptotic (Fig. 6 C, d). These results
suggest that the SRG3 protein is involved in the GC-induced
apoptosis of the thymoma cell line.
Discussion
The subunit proteins of the SWI–SNF complex were
initially identified in S. cerevisiae as transcriptional activators
of a set of genes. The SWI–SNF proteins seem to facilitate
transcription by antagonizing the repressive actions of chro-
matin (21–23). The subunit proteins seem to function as
components of a complex that associate with gene-specific
activators. Mutations in any of the subunit genes resulted in
very similar phenotypes and the phenotype of multiple de-
fective swi2 or snf 2 mutants was identical to that of a single
swi2 or snf 2 mutant (33). Besides, SWI–SNF proteins func-
tioned interdependently in transcriptional activation (32).
In addition, the SWI–SNF proteins were copurified and
coimmunoprecipitated (31, 34) and were shown to be
components of a large multisubunit complex (34, 35). Re-
cently, human SWI–SNF complexes were shown to be
present in multiple forms made up of 9–12 proteins and
several of them were purified using the BRG1 antiserum
(42, 43). There seems to exist several different forms of
SWI–SNF complexes in a single cell and in different differ-
entiated cell types (42). Based on this, it has been suggested
that these complexes are involved in tissue-specific and de-
velopmental process–specific chromatin remodeling activ-
ity needed for the differentiation of a cell (42). The human
homologues of yeast SWI3, the BAF155 and BAF170, were
Figure 5. Size fractionation of the SRG3 and SWI–SNF protein com-
plexes. After total thymocytes extract was separated on glycerol density
gradient sedimentation, the gradients were fractionated and immunoblot-
ted with the SRG3 and hSWI2 antisera. The SRG3 protein was fraction-
ated as separated complexes (300 kD) which are different from SWI2
complexes (2 MD). The blue–dextran (2 MD), thyroglobulin (669 kD),
b-amylase (200 kD), and alcohol–dehydronase (150 kD) were used as
standard molecular mass size markers.1833 Jeon et al.
also identified and the two proteins seem to exist as core
components in the same protein complex (42). SRG3
identified in the present study is homologous to human
BAF155. The overall sequences are 94% similar to each
other and the protein products are quite similar in size.
The antiserum produced against SRG3 recognized an addi-
tional 170-kD protein, which seems to correspond to hu-
man BAF170, implying that there also exists two SWI3
homologues in mouse. In spite of this similarity, the ex-
pression patterns of BAF155 and SRG3 seem to be some-
what different. BAF155 is selectively expressed in muscle
and heart but expressed at relatively low levels in liver and
brain (42); however, SRG3 is expressed at much higher
level in brain than in liver (Fig. 4 A). The selective expres-
sion patterns of BAF155 and BAF170 in different tissues
were quite similar to each other. However, mouse SRG3 is
expressed at higher level in thymus than in peripheral lym-
phoid tissues (Fig. 3); on the other hand, the 170-kD pro-
tein is expressed at similar levels in these tissues. Interest-
ingly, some SRG3 proteins and the 170 kD proteins seem
to exist independently of the SWI–SNF complex (Fig. 5).
It is not yet conclusive whether some SRG3 and 170-kD
proteins exist as heterodimers or homodimers. These re-
sults suggest that even though the human and mouse ho-
mologues of yeast SWI3 are structurally and functionally
similar, they may play distinct roles in each species and in
different tissues.
In yeast, the rat GR can activate transcription from a
promoter bearing the GR-responsive element in the pres-
ence of glucocorticoid (GC) (57, 58). It has been reported
that transcriptional activation by GR, which regulates the
expression of a network of genes in a tissue-specific man-
ner, is dependent on SWI1, SWI2, SWI3, SWP73 gene
functions in yeast (19, 59). Furthermore, SWI3 was coim-
munoprecipitated with GR in yeast extracts (19), suggest-
ing that the two proteins interact directly upon activation
of GR. Our study showed that SRG3 was highly expressed
in developing thymocytes compared with mature periph-
eral T and B lymphocytes (Fig. 3). When the level of SRG3
protein was reduced to z50–30% of normal level of thy-
moma cells by expressing anti-sense RNA to the gene, apop-
tosis induced by GC on these cells was significantly reduced
(Fig. 6). These results indicate that SRG3 is required for
GC-induced apoptosis in the thymoma cells and suggests
that SRG3 is an important factor for GC-mediated regula-
tion of thymocyte development.
It has been hypothesized that GC might affect thymo-
cyte development in a number of ways. Thymocytes re-
spond to GC by apoptosis both in vitro and in vivo (2, 60).
In vivo, the immature CD41CD81 thymocyte population
is rapidly killed in the presence of GC, whereas both the
CD42CD82 precursor population expressing no TCR2
and mature thymocytes (CD41 or CD81) cells expressing
high levels of TCR are relatively resistant. Using anti-CD3
monoclonal antibodies as a model for negative selection, it
has been found that pretreatment of mice with a GR antag-
onist, RU486, protects immature CD41CD81 thymocytes
from apoptosis (61). Furthermore, it has been reported that
radioresistent thymic epithelial cells constitutively produce
GC (12). Thus, GC and GR may function as important
regulators in normal thymic differentiation (14, 15). At this
point, it is not clear whether GC-induced apoptosis of thy-
Figure 6. Effect of SRG3 ex-
pression on GR mediated apop-
tosis. (A) Expression of the anti-
sense RNA to SRG3 in thymoma
cell line, S49.1, reduced the level
of SRG3 protein. The pRcASRG3
plasmid expressing 2.9 kb of
XbaI fragment (bases 1–2829) of
SRG3 gene in anti-sense orien-
tation under the control of CMV
promoter was transfected into
the S49.1 cells. The expression
of the SRG3 protein in trans-
fected cells was detected by im-
munoblotting using the SRG3
antiserum. lane 1, S49.1; lane 2,
vector only; lane 3, pRcASRG3
transfectant, clone A; lane 4,
pRcASRG3 transfectant, clone
B. (B) Effects of SRG3 expression
on apoptotic cell death induced
by glucocorticoid treatment.
The 10 mM of hydrocortisone
was treated for 72 h (lanes 1–4)
and the DNAs of each cell were
electrophoresed on 2% agarose
gel containing ethidium bro-
mide. The DNA fragmentation was reduced as SRG3 expression level was reduced. Lane C, control (untreated S49.1); lane 1, S49.1; lane 2, vector only;
lane 3, pRcASRG3 transfectant, clone A; lane 4, pRcASRG3 transfectant clone B. (C) FACSÒ analysis of the DNA contents of the cells transfected with
vector only (a and c) and pRcASRG3 transfectant, clone B (b and d). The subdiploid peak (closed and open arrowheads) indicates apoptotic cells induced
by glucocorticoid treatment (c and d).1834 SRG3 Required for Glucocorticoid-induced Apoptosis
moma cells requires SRG3 as a component of the SWI–
SNF complex or as a separate entity. In yeast, transcrip-
tional activation by GR is blocked by disrupting any one of
SWI1, SWI2, and SWI3 genes, suggesting the possibility
that the SWI–SNF complex is required for the GC sensi-
tivity of thymocytes. However, it is noteworthy that SRG3
protein is expressed at a much higher level in thymocytes
than in peripheral T lymphocytes and that the major part of
SRG3 protein may exist independently of the SWI–SNF
complex in thymus. Furthermore, even though the anti-
sense RNA expression reduced the level of SRG3 protein
in the transfected cells, there still remained z50% (clone A)
or 30% (clone B) of normal level of SRG3 protein (Fig. 6).
Even in the case of the clone B transfectant, this is at least
the similar level of protein found in peripheral T lympho-
cytes (Fig. 3). Therefore, it is likely that there still may be
enough SRG3 protein left to form SWI–SNF complexes in
the transfectants. These results suggest a possibility that
SRG3 protein may function independently of the SWI–
SNF complex in GC-mediated apoptosis. No matter how
SRG3 functions in GC-mediated apoptosis in thymoma
cells, either as a component of SWI–SNF complex or as an
independent factor of the complex, our present results
show that SRG3 protein is required for the process and
possibly plays an important regulatory role during thy-
mocyte development.
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